Swedish private equity group EQT has agreed to buy Qiagen, the German-Dutch maker of molecular testing and sample-preparation products, in an all-cash deal worth about €10.8bn including debt. The offer of €46.50 a share was announced on Wednesday evening with the unanimous support of Qiagen's two boards. If it succeeds, one of Europe's best-known life sciences companies will leave both the Frankfurt and New York stock exchanges.
The offer
- €46.50 a share in cash
- €10.8bn enterprise value, about $12.1bn
- 40.3% premium to the undisturbed share price
The Terms of the Offer
The bidder is Crown NL Bidco, a holding company indirectly controlled by the EQT XI fund. Two large state-backed investors are joining as co-investors: Luxinva, a wholly owned subsidiary of the Abu Dhabi Investment Authority, and CPP Investment Board Europe, part of Canada's CPP Investments.
The enterprise value of about €10.8bn includes roughly $1.1bn of net debt. The price is measured against the Xetra close of €33.15 on 8 July 2026, the last trading day before reports of private equity interest in the company. On that basis the premium is 40.3%. Against the three-month volume-weighted average price up to that date, €31.66, it is 46.9%.
Qiagen said its Supervisory Board and Managing Board reached their decision after a strategic review that included talks with both strategic and financial parties. Both boards will recommend that shareholders accept.
EQT says it has committed equity and debt financing in place, and the offer carries no financing condition. Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole and UniCredit are backing the debt.

What Has to Happen Before Closing
The offer needs acceptances covering at least 50% of Qiagen's share capital plus one share. It also depends on shareholders approving a set of post-closing measures at an extraordinary general meeting, and on merger control and foreign investment clearances.
Germany's financial regulator BaFin must approve the offer document before the acceptance period begins. Because of the New York listing, a parallel US offer will be launched, with a tender offer statement filed with the Securities and Exchange Commission.
The post-closing measures are how the buyer would reach full ownership. If the meeting backs them with at least 80% of votes cast, the boards will go ahead. If support is lower, they may still proceed if they judge it to be in Qiagen's interest and there is substantial majority support. Shareholders who did not tender would then receive a cash distribution equal to the offer price, less any withholding tax. The listings in Frankfurt and New York would end.
Key conditions and dates
- Minimum acceptance: 50% of share capital plus one share
- Shareholder vote on post-closing measures during the acceptance period
- Merger control and foreign investment approvals required
- Closing expected in mid-2027
- Possible interim dividend of up to $0.47 a share if approvals take more than 10 months
Closing is expected in mid-2027. Because that is some way off, the agreement allows Qiagen to pay an interim dividend of up to $0.47 a share if closing has not happened within 10 months of the announcement because regulatory approvals are still pending. That payment would not be deducted from the offer price.
Why EQT Wants Qiagen
Qiagen sells the tools used to extract and analyse DNA and RNA in research labs, hospitals and testing centres. It serves more than 500,000 customers and employed about 5,400 people at more than 35 locations at the end of September.
EQT, which manages about €354bn, has invested more than €30bn in over 210 healthcare companies. Its past and current holdings include Galderma, Parexel, Aldevron, Dako and HemoCue. Matteo Thun-Hohenstein, a partner at EQT, called Qiagen a global leader in life science tools and diagnostics.
EQT has made commitments on Qiagen's strategy, key brands, operating footprint, research and development, employees and corporate culture. The company is expected to keep its name, and its current management will continue to run it independently until the deal closes.
Chief executive Jonathan M. Pratt argued that private ownership would let the company "move faster and have greater freedom" to invest behind its priorities. The usual case for a take-private is that long-term spending on new instruments and tests can be planned without the pressure of quarterly reporting.
What It Means for Shareholders
For investors the offer sets a reference point well above where the shares traded before the summer reports. The 40% premium is measured against the undisturbed July price, so it says nothing about how far the shares may have moved since takeover talk began.
Several steps still lie ahead. The offer document, with the exact acceptance period, is yet to be published. Shareholders will then decide whether to tender or wait, knowing that the post-closing measures are designed to bring in those who do not. Because the cash distribution to those who stay out is paid after any withholding tax, the details in the offer document will matter. The announcement also lists the possibility of a competing offer among the risks to the deal.







